Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

A 4-gene signature associated with clinical outcome in high-grade gliomas.

de Tayrac M, Aubry M, Saïkali S, Etcheverry A, Surbled C, Guénot F, Galibert MD, Hamlat A, Lesimple T, Quillien V, Menei P, Mosser J.

Clin Cancer Res. 2011 Jan 15;17(2):317-27. doi: 10.1158/1078-0432.CCR-10-1126. Epub 2011 Jan 11.

2.

Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood.

Bredel M, Pollack IF, Hamilton RL, James CD.

Clin Cancer Res. 1999 Jul;5(7):1786-92.

3.

Gene expression profile as a prognostic factor in high-grade gliomas.

Czernicki T, Zegarska J, Paczek L, Cukrowska B, Grajkowska W, Zajaczkowska A, Brudzewski K, Ulaczyk J, Marchel A.

Int J Oncol. 2007 Jan;30(1):55-64.

PMID:
17143512
4.

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY.

J Clin Oncol. 2009 Sep 1;27(25):4150-4. doi: 10.1200/JCO.2009.21.9832. Epub 2009 Jul 27.

PMID:
19636000
5.

The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.

Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, Kurc T, Saltz JH, Brat DJ, Moreno CS.

PLoS One. 2010 Sep 3;5(9):e12548. doi: 10.1371/journal.pone.0012548.

6.

Gene expression profiling of gliomas strongly predicts survival.

Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF.

Cancer Res. 2004 Sep 15;64(18):6503-10.

7.

Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival.

Schittenhelm J, Trautmann K, Tabatabai G, Hermann C, Meyermann R, Beschorner R.

Mod Pathol. 2009 Dec;22(12):1600-11. doi: 10.1038/modpathol.2009.132. Epub 2009 Sep 18.

8.

Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.

Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, De Moor B, Eilers PH, van der Spek PJ, Kros JM, Sillevis Smitt PA, van den Bent MJ, French PJ.

Cancer Res. 2009 Dec 1;69(23):9065-72. doi: 10.1158/0008-5472.CAN-09-2307. Epub 2009 Nov 17.

9.

Beyond grade: molecular pathology of malignant gliomas.

Sulman EP, Guerrero M, Aldape K.

Semin Radiat Oncol. 2009 Jul;19(3):142-9. doi: 10.1016/j.semradonc.2009.02.001.

PMID:
19464628
11.

Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.

Marko NF, Prayson RA, Barnett GH, Weil RJ.

Genomics. 2010 Jan;95(1):16-24. doi: 10.1016/j.ygeno.2009.09.007. Epub 2009 Oct 14.

12.

The use of global profiling in biomarker development for gliomas.

Sulman EP, Aldape K.

Brain Pathol. 2011 Jan;21(1):88-95. doi: 10.1111/j.1750-3639.2010.00456.x. Review.

PMID:
21129062
13.

Molecular analysis of CDKN2 (p16) in gliomas associated with clinical data.

De Souza Nascimento P, Maciel CM, Kawamura MT, Oliveira JA, Teixeira A, Carvalho Mda G, Alves G.

Oncol Rep. 2001 Sep-Oct;8(5):1039-43.

PMID:
11496313
14.

Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker.

Hägerstrand D, Smits A, Eriksson A, Sigurdardottir S, Olofsson T, Hartman M, Nistér M, Kalimo H, Ostman A.

Neuro Oncol. 2008 Feb;10(1):2-9. Epub 2007 Nov 14.

15.

Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival.

Korkolopoulou P, Kouzelis K, Christodoulou P, Papanikolaou A, Thomas-Tsagli E.

Acta Neuropathol. 1998 Jun;95(6):617-24.

PMID:
9650754
16.

Quantitative PCR analysis of the expression profile of genes related to multiple drug resistance in tumors of the central nervous system.

Valera ET, Lucio-Eterovic AK, Neder L, Scrideli CA, Machado HR, Carlotti-Junior CG, Queiroz RG, Motta FJ, Tone LG.

J Neurooncol. 2007 Oct;85(1):1-10. Epub 2007 Apr 12.

PMID:
17429576
17.

Low-grade gliomas: management issues.

Duran I, Raizer JJ.

Expert Rev Anticancer Ther. 2007 Dec;7(12 Suppl):S15-21. doi: 10.1586/14737140.7.12s.S15. Review.

PMID:
18076313
18.

Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors.

Todaro L, Christiansen S, Varela M, Campodónico P, Pallotta MG, Lastiri J, Sacerdote de Lustig E, Bal de Kier Joffé E, Puricelli L.

J Neurooncol. 2007 Jun;83(2):135-44. Epub 2007 Jan 10.

PMID:
17216340
19.

Association of telomerase gene hTERT polymorphism and malignant gliomas.

Carpentier C, Lejeune J, Gros F, Everhard S, Marie Y, Kaloshi G, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Sanson M.

J Neurooncol. 2007 Sep;84(3):249-53. Epub 2007 Apr 5.

PMID:
17410334
20.

Prognostic stratification of patients with anaplastic gliomas according to genetic profile.

Dehais C, Laigle-Donadey F, Marie Y, Kujas M, Lejeune J, Benouaich-Amiel A, Pedretti M, Polivka M, Xuan KH, Thillet J, Delattre JY, Sanson M.

Cancer. 2006 Oct 15;107(8):1891-7.

Supplemental Content

Support Center